Aadi Bioscience Stock Working Capital
| AADIDelisted Stock | USD 2.05 0.05 2.38% |
Aadi Bioscience fundamentals help investors to digest information that contributes to Aadi Bioscience's financial success or failures. It also enables traders to predict the movement of Aadi Stock. The fundamental analysis module provides a way to measure Aadi Bioscience's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aadi Bioscience stock.
Aadi |
Aadi Bioscience Company Working Capital Analysis
Aadi Bioscience's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Aadi Bioscience Working Capital | 98.19 M |
Most of Aadi Bioscience's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aadi Bioscience is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
In accordance with the company's disclosures, Aadi Bioscience has a Working Capital of 98.19 M. This is 76.93% lower than that of the Biotechnology sector and 81.77% lower than that of the Health Care industry. The working capital for all United States stocks is 93.36% higher than that of the company.
Aadi Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aadi Bioscience's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aadi Bioscience could also be used in its relative valuation, which is a method of valuing Aadi Bioscience by comparing valuation metrics of similar companies.Aadi Bioscience is currently under evaluation in working capital category among its peers.
Aadi Fundamentals
| Return On Equity | -0.66 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (2.46) % | ||||
| Operating Margin | (1.49) % | ||||
| Current Valuation | 35.53 M | ||||
| Shares Outstanding | 46.29 M | ||||
| Shares Owned By Insiders | 6.09 % | ||||
| Shares Owned By Institutions | 50.02 % | ||||
| Number Of Shares Shorted | 764.36 K | ||||
| Price To Book | 1.41 X | ||||
| Price To Sales | 3.88 X | ||||
| Revenue | 24.35 M | ||||
| Gross Profit | (27.54 M) | ||||
| EBITDA | (65.36 M) | ||||
| Net Income | (65.77 M) | ||||
| Cash And Equivalents | 118.74 M | ||||
| Cash Per Share | 5.65 X | ||||
| Total Debt | 1.27 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 9.87 X | ||||
| Book Value Per Share | 2.80 X | ||||
| Cash Flow From Operations | (59.66 M) | ||||
| Short Ratio | 8.87 X | ||||
| Earnings Per Share | (2.28) X | ||||
| Target Price | 3.0 | ||||
| Number Of Employees | 53 | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 97.21 M | ||||
| Total Asset | 132.42 M | ||||
| Retained Earnings | (268.96 M) | ||||
| Working Capital | 98.19 M | ||||
| Net Asset | 132.42 M |
About Aadi Bioscience Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aadi Bioscience's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aadi Bioscience using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aadi Bioscience based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aadi Bioscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Other Consideration for investing in Aadi Stock
If you are still planning to invest in Aadi Bioscience check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aadi Bioscience's history and understand the potential risks before investing.
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |